IP Library Granted Patent US 8,513,279
Granted Patent B2
US 8,513,279 · App. 13/354,873 · Granted Aug 20, 2013

Quinuclidine derivatives and medicinal compositions containing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,513,279
App. No.
13/354,873
Granted
Aug 20, 2013
Kind
B2
Abstract

The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in combination with a steroid, and methods of using it for treatment of respiratory disorders.

Claims (14)

1. A pharmaceutical composition comprising:

(i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X − with a single negative charge is associated with the positive charge of the nitrogen atom; and

(ii) a steroid.

2. The composition of claim 1 further comprising a pharmaceutically acceptable carrier or diluent.

3. The composition of claim 1 wherein the anion X − is chloride, bromide, iodide, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p-toluenesulfonate, or trifluoroacetate.

4. The composition of claim 1 which is suitable for inhalation.

5. The composition of claim 1 wherein the composition is a liquid inhalant, powder inhalant, or inhalation aerosol.

6. The composition of claim 1 further comprising a phosphodiesterase IV inhibitor.

7. The composition of claim 6 further comprising a β 2 agonist.

8. The composition of claim 1 further comprising a β2 agonist.

9. The composition of claim 2 wherein the pharmaceutically acceptable carrier or diluent is lactose.

10. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of the composition of claim 1 .

11. The method of claim 10 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.

12. The method of claim 11 further comprising administering an effective amount of β2 agonist.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: FERNANDEZ FORNER, MARIA DOLORS; PRAT QUINONES, MARIA; BUIL ALBERO, MARIA ANTONIA
To: ALMIRALL PRODESFARMA, S.A.
Reel/Frame 042416/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: ALMIRALL PRODESFARMA, S.A.
To: ALMIRALL PRODESFARMA AG
Reel/Frame 042416/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: ALMIRALL AG
To: LABORATORIOS ALMIRALL, S.A.
Reel/Frame 042417/0118 →
CHANGE OF NAME Recorded May 17, 2017
From: ALMIRALL PRODESFARMA AG
To: ALMIRALL AG
Reel/Frame 042490/0468 →
CHANGE OF NAME Recorded May 17, 2017
From: LABORATORIOS ALMIRALL, S.A.
To: ALMIRALL, S.A.
Reel/Frame 042490/0721 →